Clinical Trial of Sutent to Treat Metastatic Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Metastatic Melanoma
Interventions
DRUG

Sutent (sunitinib)

The initial dose will be 50mg daily taken for 4 consecutive weeks followed by 2-weeks off to comprise a complete cycle of 6 weeks.

Trial Locations (1)

94115

California Pacific Medical Center, San Francisco

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

collaborator

University of California, San Francisco

OTHER

lead

California Pacific Medical Center Research Institute

OTHER